SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the ...
JD Supra

SEC rescinds SAB 121 - What it Means for Financial Institutions and Crypto Exchanges

Controversial Securities and Exchange Commission accounting guidance known as SAB 121 has been rescinded. SAB 121 has been viewed as a significant obstacle preventing banks from providing custody ...

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting

Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization ...
CoinTelegraph

SAB 121 rescinded: What it means for crypto custody and regulation in 2025

The Staff Accounting Bulletin (SAB) 121 rule was introduced by the SEC in March 2022 as part of its efforts to regulate cryptocurrency custody. It required financial institutions to list any crypto ...
Bitcoin Magazine

Preston Pysh Explains Why SAB 121 Beats a Strategic Bitcoin Reserve

Preston Pysh explains how the rescission of SAB 121 could permanently entrench Bitcoin into the financial system, surpassing the importance of a Strategic Bitcoin Reserve. In the rapidly evolving ...
Nasdaq

SAB BIO Secures $175 Million in Private Placement Financing to Advance Phase 2b SAFEGUARD Study for Autoimmune T1D Treatment

SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...
Yahoo Finance

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
FierceBiotech

SAB vows to plow ahead with COVID-19 therapy after NIH drops out

SAB Biotherapeutics is hoping to continue work on its COVID-19 antibody treatment after the National Institutes of Health (NIH) shut down a funded phase 3 clinical trial when the omicron wave slowed ...
Yahoo Finance

SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza

SIOUX FALLS, S.D., April 13, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
اخبار 24

Saudi Awwal Bank

SAB’s 9M 2025 net profit rises to SAR 6.41B; Q3 at SAR 2.14B 9 M 2025 SAB profit up 5% to SAR 4.3B in H1 2025; Q2 at SAR 2.1B 6 M 2025 SAB profit rises 5% to SAR 2.13B in Q1 2025 3 M 2025 SAB's 2024 ...
News24

SAB gets new logo – which represents SA future with 'more cheers'

SAB has launched a new, more modern logo. Its CEO believes better times lie ahead for South Africa thanks to a growing youthful population. A merged Heineken and Distell group could bring more ...